The Latest Breaking News from Steris

STERIS has outpaced its industry peers over the past year, and analysts are reasonably bullish on its future prospects.

While STERIS has underperformed the broader market over the past year, analysts are highly optimistic about the stock’s prospects.

STERIS has underperformed the S&P 500 over the past year, yet analysts remain moderately bullish about the stock’s potential.

The healthcare industry's long-term growth is fueled by rising R&D initiatives and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid medical device stocks Alcon (ALC), Becton, Dickinson and Company (BDX), and STERIS (STE) for potential returns. Keep reading.

STERIS has underperformed the broader market over the past year, yet analysts remain moderately bullish on the stock’s potential.

Upgrades

Thailand Board of Investment (BOI), Paris Office, cordially invites companies to join its webinar on Business and Investment Opportunities in the Medical Sector in Thailand with BOI Headquarters, Bangkok Dusit Medical Service (BDMS), Thai Food and Drug Administration (FDA), Sanet Asean Advisors, and STERIS (AST)

If history is any guide, there may be trouble ahead for shares of Steris (NYSE:STE). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Steris (NYSE:STE) reported its Q4 earnings results on Wednesday, May 11, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Steris beat estimated earnings by 0.99%, reporting an EPS of $2.04 versus an estimate of $2.02.